XX医科大学第一附属医院肿瘤内科《乳腺癌的内科治疗进展》讲稿.pptVIP

The RIBBON-1 trial was not designed or powered to detect a difference in overall survival. At the time of this analysis, survival results were immature, with events in only 33% of patients. However, there was a trend towards improved overall survival with Xeloda-Avastin versus Xeloda-placebo (median 29.0 versus 21.2 months, HR=0.85, p=0.27).1 At disease progression patients in the placebo arm were permitted to cross over to the Avastin arm, 69% of Xeloda-placebo patients went on to receive second-line Avastin and this may have confounded the overall survival results. 1. Robert N, et al. J Cl